Cytomed TherapeuticsGDTC
13F holders, Q1 2026 (March 31)3holders −2
1new positions
3sold out
$1.00avg. 13F price*
At the end of Q1 2026, 3 institutions reported holding Cytomed Therapeutics Ltd. (GDTC) in their 13F filings, down 2 from Q4 2025. 1 opened new positions and 3 sold out. The largest holders were XTX Topco Ltd ($10K), UBS Group AG ($6K) and Osaic Holdings, Inc. ($21).
- Company
- Cytomed Therapeutics Ltd.
- CUSIP
- Y1R80M106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $10K |
| Exits | 3 | $69K |
All 13F filers, Q4 2025 → Q1 2026: 15,253 shares bought and 52,042 shares sold, net −36,789 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| XTX Topco Ltd | 0.00% | New | 10,136 | $10K |
| UBS Group AG | 0.00% | Add +480.5% | 6,182 | $6K |
| Osaic Holdings, Inc. | 0.00% | No change | 21 | $21 |
"% of holder's portfolio" is GDTC's weight in each manager's 13F, not the share of Cytomed Therapeutics Ltd. the manager owns.